PayenDMGuilhotJLauneyY, et al. Early use of polymyxin B-immobilezed fiber column for treatment of severe hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. Intensive Care Med2015; 41:975–984.
2.
AntonelliMCutuliSLRoncoC. Polymyxin B hemoperfusion in septic shock: just look at the evidence!Intensive Care Med2015; 41:1731–1732.
3.
DellingerRPBagshawSMAntonelliM, et al. Effect of targeted polymyxin B hemoperfusion on 28-Day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA2018; 320(14): 1455–1463.
4.
StahlKWendel GarciaPDBodeC, et al. Unraveling the secret of re-balancing homeostasis in sepsis: a critical view on extracorporeal blood purification modalities. Intensive Care Med2022; 48(1): 130–132.
5.
DavidSBodeCPutensenC, et al. Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med2021; 47(3): 352–354.
6.
Wendel GarciaPDHiltyMPHeldU, et al. Cytokine adsorption in severe, refractory septic shock. Intensive Care Med2021; 47(11): 1334–1336.
7.
GarberoELivigniSFerrariF, et al. High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med2021; 47(11): 1303–1311.
8.
RuggCKloseRHornungR, et al. Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective ‘Genetic’ matched analysis. Biomedicines2020; 8(12): 539.
9.
BrouwerWPDuranSKuijperM, et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care2019; 23(1): 317.
10.
BrouwerWPDuranSInceC. Improved survival beyond 28 days up to 1 year after CytoSorb treatment for refractory septic shock: A propensity-weighted retrospective survival analysis. Blood Purif2021; 50(4-5): 539–545.
11.
RoncoCTettaCMarianoF, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis.. Artif Organs2003; 27:792–801.
12.
BottariGMerliPGuzzoI, et al. Multimodal therapeutic approach of cytokine release syndrome developing in a child given chimeric antigen receptor-modified T cell infusion. Crit Care Explor2020; 2(1): e0071–e0071.
13.
SchultzPSchwierEEickmeyerC, et al. High-dose CytoSorb hemoadsorption is associated with improved survival in patients with septic shock: a retrospective cohort study. J Crit Care2021; 64:184–192.
